Meta-analysis: Adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus

Virology Journal

Volumn 6, Issue , 2009, Pages

  Chen, En Qiang ^a,b   Wang, Li Chun ^a,b   Lei, Jun ^a,b   Xu, Lu ^a,b  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; HEPATITIS E ANTIGEN; LAMIVUDINE; ADENINE; ANTIVIRUS AGENT; DRUG DERIVATIVE; PHOSPHONIC ACID DERIVATIVE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; META ANALYSIS; MONOTHERAPY; NONHUMAN; SEROCONVERSION; SYSTEMATIC REVIEW; VIRUS INHIBITION; VIRUS MUTANT; VIRUS RESISTANCE; ANTIVIRAL RESISTANCE; DRUG EFFECT; REVIEW; TREATMENT OUTCOME;

HEPATITIS B VIRUS;

ADENINE; ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, VIRAL; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; PHOSPHONIC ACIDS; TREATMENT OUTCOME;

EID: 70350346876     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-6-163     Document Type: Article

References (34)

1. Chronic hepatitis B: update of recommendations. AS Lok BJ McMahon, Hepatology 2004 39 857 861 10.1002/hep.20110 14999707
2. Lamivudine for patients with chronic hepatitis B and advanced liver disease. YF Liaw JJ Sung WC Chow G Farrell CZ Lee H Yuen T Tanwandee QM Tao K Shue ON Keene JS Dixon DF Gray J Sabbat Cirrhosis Asian Lamivudine Multicentre Study Group, N Engl J Med 2004 351 1521 1531 10.1056/NEJMoa033364 15470215
3. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. JM Pawlotsky G Dusheiko A Hatzakis D Lau G Lau TJ Liang S Locarnini P Martin DD Richman F Zoulim, Gastroenterology 2008 134 405 415 10.1053/j.gastro.2007.11.036 18242209
4. Management of chronic hepatitis B. HS Conjeevaram AS Lok, J Hepatol 2003 38 90 103 10.1016/S0168-8278(02)00431-2 12591188
5. Treatment of chronic hepatitis B. SR Mohanty SS Kupfer V Khiani, Nat Clin Pract Gastroenterol Hepatol 2006 3 446 458 10.1038/ncpgasthep0550 16883349
6. Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine. S Manolakopoulos S Bethanis S Koutsounas J Goulis J Vlachogiannakos E Christias A Saveriadis C Pavlidis C Triantos A Christidou G Papatheodoridis D Karamanolis D Tzourmakliotis, Aliment Pharmacol Ther 2008 27 266 273 17988233
7. Clinical course of lamivudine monotherapy in patients with decompensated cirrhosis due to HBeAg negative chronic HBV infection. S Manolakopoulos S Karatapanis J Elefsiniotis N Mathou J Vlachogiannakos E Iliadou A Kougioumtzan M Economou C Triantos D Tzourmakliotis A Avgerinos, Am J Gastroenterol 2004 99 57 63 10.1046/j.1572-0241.2003.04021.x 14687142
8. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. GV Papatheodoridis E Dimou K Dimakopoulos S Manolakopoulos I Rapti G Kitis D Tzourmakliotis E Manesis SJ Hadziyannis, Hepatology 2005 42 121 129 10.1002/hep.20760 15962291
9. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. SJ Hadziyannis NC Tassopoulos EJ Heathcote TT Chang G Kitis M Rizzetto P Marcellin SG Lim Z Goodman MS Wulfsohn S Xiong J Fry CL Brosgart Adefovir Dipivoxil 438 Study Group, N Engl J Med 2003 348 800 807 10.1056/NEJMoa021812 12606734 (Pubitemid 36245756)
10. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. P Marcellin TT Chang SG Lim MJ Tong W Sievert ML Shiffman L Jeffers Z Goodman MS Wulfsohn S Xiong J Fry CL Brosgart Adefovir Dipivoxil 437 Study Group, N Engl J Med 2003 348 808 816 10.1056/NEJMoa020681 12606735 (Pubitemid 36245757)
11. Adefovir dipivoxil: a review of its use in chronic hepatitis B. T Dando G Plosker, Drugs 2003 63 2215 2234 10.2165/00003495-200363200-00007 14498759
12. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. P Lampertico M Vigan E Manenti M Iavarone G Lunghi M Colombo, Hepatology 2005 42 1414 1419 10.1002/hep.20939 16317671
13. Adefovir dipivoxil is effective for the treatment of cirrhotic patients with lamivudine failure. F Zoulim P Parvaz P Marcellin JP Zarski M Beaugrand Y Benhamou F Bailly M Maynard C Trepo A Trylesinski F Monchecourt VIRESPA study group, Liver Int 2009 29 420 426 10.1111/j.1478-3231.2008.01867.x 18795900
14. EASL Clinical Practice Guidelines:Management of chronic hepatitis B. European Association for the Study of the Liver, Journal of Hepatology 2009 50 227 42 10.1016/j.jhep.2008.10.001 19054588
15. Benefits and risks of combination therapy for hepatitis B. NA Terrault, Hepatology 2009 49 122 S128 19399796
16. Adefovir dipivoxil monotherapy and combination therapy with lamivudine for the treatment of chronic hepatitis B in an Asian population. J Fung CL Lai JC Yuen DK Wong Y Tanaka M Mizokami MF Yuen, Antivir Ther 2007 12 41 46 17503746
17. Short-term overlap lamivudine treatment with adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B. SW Nam SH Bae SW Lee YS Kim SB Kang JY Choi SH Cho SK Yoon JY Han JM Yang YS Lee, World J Gastroenterol 2008 14 1781 1784 10.3748/wjg.14.1781 18350610
18. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. R Perrillo HW Hann D Mutimer B Willems N Leung WM Lee A Moorat S Gardner M Woessner E Bourne, et al. Gastroenterology 2004 126 81 90 10.1053/j.gastro.2003.10.050 14699490
19. Lamivudine-resistant chronic hepatitis B: an observational study on adefovir in monotherapy or in combination with lamivudine. S Gaia V Barbon A Smedile A Olivero S Carenzi M Lagget C Alessandria M Rizzetto A Marzano, J Hepatol 2008 48 540 547 10.1016/j.jhep.2007.12.018 18279995
20. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. MG Peters HwH Hann P Martin EJ Heathcote P Buggisch R Rubin M Bourliere K Kowdley C Trepo DfD Gray, et al. Gastroenterology 2004 126 91 101 10.1053/j.gastro.2003.10.051 14699491
21. Emergence of adefovir-resistant mutants after reversion to YMDD wild-type in lamivudine-resistant patients receiving adefovir monotherapy. HC Kwon JY Cheong SW Cho JM Choi SP Hong SO Kim WD Yoo, J Gastroenterol Hepatol 2009 24 49 54 10.1111/j.1440-1746.2008.05570.x 19196395
22. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. I Rapti E Dimou P Mitsoula SJ Hadziyannis, Hepatology 2007 45 307 313 10.1002/hep.21534 17256746
23. Dynamics of lamivudine-resistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapy. S Ijaz C Arnold S Dervisevic J Mechurova N Tatman RS Tedder NV Naoumov, J Med Virol 2008 80 1160 1170 10.1002/jmv.21206 18461609
24. Study of adefovir on treatment of chronic hepatitis B patients with resistance to lamivudine: a year's clinical course. Y Xiao JL zheng WJ Zhang YJ Zhou CH Hu X Hu CH Lu HJ Pan, Chinese Hepatology 2008 13 295 298
25. Effect of adefovir and lamivudine combination therapy on lamivudine resistance patients. PY Yang SH Liu B Feng, J Fourth Mil Med Univ 2008 29 155 157
26. Adefovir dipivoxil alone or in combination with lamivudine in treating patients with chronic HBeAg-positive hepatitis B resistant to the treatment of lamivudine. XP Chen YC Li SG Wu C Chen, Journal of Guangdong Medical college 2008 26 23 25
27. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. NW Leung CL Lai TT Chang R Guan CM Lee KY Ng SG Lim PC Wu JC Dent S Edmundson LD Condreay RN Chien Asia Hepatitis Lamivudine Study Group, Hepatology 2001 33 1527 1532 10.1053/jhep.2001.25084 11391543
28. Adefovir dipivoxil alone or in combination with lamivudine for three months in patients with lamivudine resistant compensated chronic hepatitis B. M Akyildiz F Gunsar G Ersoz Z Karasu T Ilter Y Batur U Akarca, Dig Dis Sci 2007 52 3444 3447 10.1007/s10620-006-9718-8 17431777
29. Antiviral drug resistance: clinical consequences and molecular aspects. A Bartholomeusz SA Locarnini, Semin Liver Dis 2006 26 162 170 10.1055/s-2006-939758 16673294
30. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up. H Yatsuji F Suzuki H Sezaki N Akuta Y Suzuki Y Kawamura T Hosaka M Kobayashi S Saitoh Y Arase, et al. J Hepatol 2008 48 923 931 10.1016/j.jhep.2008.02.019 18433925
31. Adefovir and lamivudine combination therapy is superior to ADV monotherapy for lamivudine-resistant patients with HBeAG-negative chronic hepatitis B. P Lampertico A Marzano M Levrero T Santantonio V Di Marco M Brunetto P Andreone E Sagnelli S Fagiuoli G Mazzella G Raimondo GB Gaeta A Ascione On behalf of the AISF Adefovir Study Group, Digestive and Liver Disease 2007 39 7 10.1016/j.dld.2006.12.036
32. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. S Villet C Pichoud G Billioud L Barraud S Durantel C Trepo F Zoulim, J Hepatol 2008 48 747 755 10.1016/j.jhep.2008.01.027 18331765
33. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. P Lampertico M Vigano E Manenti M Iavarone E Sablon M Colombo, Gastroenterology 2007 133 1445 1451 10.1053/j.gastro.2007.08.079 17983801
34. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. JJ Sung JY Lai S Zeuzem WC Chow EJ Heathcote RP Perrillo CL Brosgart MA Woessner SA Scott DF Gray SD Gardner, J Hepatol 2008 48 728 735 10.1016/j.jhep.2007.12.026 18329126